An oil-in-water nanoemulsion in which the oil globules have a mean size of less than 100 nm and which contains an amphiphilic lipid component containing at least one non-ionic amphiphilic lipid which is liquid at an ambient temperature of less than 45°C The nanoemulsion can be used in the fields of cosmetics and dermopharmaceuticals. The nanoemulsion is stable on storage, can contain significant amounts of oil while retaining good transparency, and can contain heat-sensitive active agents.

Patent
   5753241
Priority
Feb 27 1995
Filed
Feb 26 1996
Issued
May 19 1998
Expiry
Feb 26 2016
Assg.orig
Entity
Large
137
4
all paid
1. An oil-in-water nanoemulsion comprising water, oil globules having a mean size of less than 100 nm dispersed in an aqueous phase and an amphiphilic lipid component situated at the oil/aqueous phase interface wherein the amphiphilic lipid component comprises at least one non-ionic amphiphilic lipid which is liquid at a temperature of less than 45° C. and wherein the ratio by weight of the amount of oil to the amount of amphiphilic lipid component is from 3 to 10.
2. The nanoemulsion according to claim 1, wherein the non-ionic amphiphilic lipid is an ester or a mixture of esters of at least one polyol, selected from the group consisting of polyethylene glycol containing from 1 to 60 ethylene oxide units, sorbitan, glycerol containing from 2 to 30 ethylene oxide units and polyglycerol containing from 2 to 15 glycerol units, with at least one fatty acid containing at least one saturated or unsaturated, linear or branched, C8 -C22 alkyl chain.
3. The nanoemulsion according to claim 1 wherein the ratio by weight of the amount of oil to the amount of amphiphilic lipid component is from 3 to 6.
4. The nanoemulsion according to claim 1 wherein the amphiphilic lipid component further comprises at least one ionic amphiphilic lipid.
5. The nanoemulsion according to claim 4, wherein the at least one ionic amphiphilic lipid is selected from the group consisting of neutralized anionic lipids, amphoteric ionic lipids and alkylsulphonic derivatives.
6. The nanoemulsion according to claim 4 wherein the at least one ionic amphiphilic lipid is selected from the group consisting of:
alkaline salts of dicetyl and dimyristyl phosphate;
alkaline salts of cholesterol sulphate;
alkaline salts of cholesterol phosphate;
salts of amino acids containing fatty groups;
sodium salts of phosphatidic acid;
phospholipids; and
alkylsulphonic derivatives of formula: ##STR2## in which R represents C16 -C22 alkyl radicals, taken as a mixture or separately, and M is an alkali metal.
7. The nanoemulsion according to claim 4 wherein the ionic amphiphilic lipid is present in concentrations ranging from 2 to 10% by weight with respect to the total weight of the amphiphilic lipid component.
8. The nanoemulsion according to claim 1 wherein the proportion of oil is from 5 to 30% by weight with respect to the total weight of the nanoemulsion.
9. The nanoemulsion according to claim 1 wherein the oil is selected from the group consisting of:
animal or vegetable oils formed by esters of fatty acids and of polyols
vegetable or animal oils of formula R9 COOR10, in which R9 represents the residue of a higher fatty acid containing from 7 to 19 carbon atoms and R10 represents a branched hydrocarbon chain containing from 3 to 20 carbon atoms;
natural or synthetic essential oils;
hydrocarbons;
halogenated hydrocarbons;
esters of an inorganic acid and of an alcohol;
ethers and polyethers; and
silicones, as a mixture with at least one of the oils defined above.
10. The nanoemulsion according to claim 1 further comprising an additive that improves transparency.
11. The nanoemulsion according to claim 10, wherein the additive is a lower alcohol or glycol.
12. The nanoemulsion according to claim 11 wherein the additive is present in concentrations ranging from 5 to 30% by weight with respect to the total weight of the nanoemulsion.
13. The nanoemulsion according to claim 12, said nanoemulsion containing a lower alcohol in a concentration ranging from 5 to 20% by weight with respect to the total weight of the emulsion.
14. The nanoemulsion according to claim 12, said nanoemulsion containing a glycol in concentrations ranging from 2 to 15% by weight with respect to the total weight of the emulsion.
15. The nanoemulsion according to claim 11, said nanoemulsion comprising at least 15% by weight of said lower alcohol with respect to the total weight of the composition.
16. The nanoemulsion according to claim 1 further comprising a water-soluble or liposoluble cosmetic or dermopharmaceutical active agent.
17. The nanoemulsion according to claim 1, further comprising an additive selected from the group consisting of gelling agents, preservatives and fragrances.
18. The nanoemulsion according to claim 1 wherein the oil globules have a mean size ranging from 30 to 75 nm.
19. The nanoemulsion according to claim 1 wherein the oil globules have a mean size ranging from 40 to 60 nm.
20. The nanoemulsion according to claim 1, wherein said nanoemulsion has a transparency, determined by the transmittance coefficient, measured at a wavelength of 600 nm, ranging from 30 to 90%.
21. A composition for topical use comprising the nanoemulsion according to claim 1.
22. A process for the treatment of the skin and/or of the scalp, comprising applying a nanoemulsion according to claim 1 to the skin and/or the scalp.
23. A process for the preparation of the nanoemulsion as defined in claim 1, comprising mixing an aqueous phase and an oily phase together with stirring at a temperature of less than 45°C to form a mixture and then carrying out high-pressure homogenization at a pressure greater than 108 Pa on said mixture.
24. The process according to claim 23, wherein the pressure is from 12×107 to 18×107 Pa.

The present invention relates to an oil-in-water nanoemulsion which is preferably transparent and in which the oil globules have a mean size of less than 100 nm. The invention nanoemulsion further preferably comprises an amphiphilic lipid component based on at least one non-ionic amphiphilic lipid which is liquid at temperatures less than 45°C The invention nanoemulsion is useful for the topical application of, in particular, cosmetics, skin conditioners, and dermopharmaceuticals.

Oil-in-water emulsions are well-known in the field of cosmetics, dermopharmaceuticals, etc., in particular for the preparation of cosmetic products such as lotions, tonics, serums or toilet waters. Transparent microemulsions are also known. Microemulsions are not, strictly speaking, emulsions; these are transparent solutions of micelles, that is to say that the oil present is dissolved therein by virtue of the joint presence of surfactants and of cosurfactants and by virtue, generally, of a high proportion of these surfactants and cosurfactants. The extremely small size of the particles, which is the cause of their transparency, arises from this "solubilization". The disadvantages of these microemulsions, however, are related to their high proportion of surfactants, leading to intolerances and resulting in a sticky feel during application to the skin. Thus, EP-A-572,080 describes microemulsions containing an oil, a fragrance and a mixture of surfactant and of cosurfactant, the proportion of oil and of mixture of surfactant and cosurfactant being between 0.85 and 2.5.

Nanoemulsions comprising oil globules having a mean size of less than 100 nm have already been used in order to obtain transparent compositions having an appearance similar to water and resulting, after application to the skin, in a feel similar to that of a cream or milk. These nanoemulsions, in contrast to microemulsions, are true emulsions where the oil globules are dispersed in an aqueous phase, the surfactants being situated at the oil/aqueous phase interface. The transparency of these emulsions arises from the small size of the oily globules, which small size is obtained by virtue of passing through a high- pressure homogenizer.

Nanoemulsions comprising an amphiphilic lipid phase composed of phosphoglycerides, water and oil are known. These emulsions have the disadvantage of being unstable on storage at conventional storage temperatures, namely between 0° and 45°C They result in yellow compositions and produce a rancid smell which develops after a few days of storage. They are described in EP 406 162.

Nanoemulsions comprising the combination of a long-chain fatty alcohol and/or of a long-chain fatty acid and of a soap type surfactant of a long-chain fatty acid forming a gel, the phase transition temperature of which is greater than 60°C, are also known. These emulsions are prepared at temperatures greater than 70°C which limit the use of heat-sensitive active principles in such compositions. They are described, for example, in EP-A-615,741.

The inventors have unexpectedly discovered new nanoemulsions exhibiting all the advantages of known nanoemulsions without their disadvantages nor the disadvantages of microemulsions. The invention nanoemulsions have oil globules whose mean size is less than 100 nm, and they are stable on storage between 0° and 45°C for at least two months. The nanoemulsions in accordance with the invention are preferably prepared at temperatures between 20° and 450°C and are compatible with heat-sensitive active principles. They can contain significant amounts of oil, while retaining good transparency properties. They can particularly contain significant amounts of fragrance and can improve their persistence. They also promote penetration of the active principles into the surface layers of the skin.

The subject of the present invention is an oil-in-water nanoemulsion having oil globules, the mean size of which is less than 100 nm, and comprising an amphiphilic lipid component, characterized in that the amphiphilic lipid component comprises at least one non-ionic amphiphilic lipid which is liquid at a temperature of less than 45°C and that the ratio by weight of the amount of oil to the amount of amphiphilic lipid component varies from 2 to 10. The invention nanoemulsions are water-containing nanoemulsions.

The amphiphilic non-ionic lipids of the invention are preferably chosen from esters or mixtures of esters of at least one polyol, preferably chosen from polyethylene glycol containing from 1 to 60 ethylene oxide units, sorbitan, glycerol containing from 2 to 30 ethylene oxide units or polyglycerols containing from 2 to 15 glycerol units, with at least one fatty acid containing at least one saturated or unsaturated, linear or branched, C8 -C22 alkyl chain.

Mention may be made, by way of example, of

the isostearate of polyethylene glycol with a molecular weight of 400, sold under the name PEG 400 isostearate by the company Unichema;

diglyceryl isostearate, sold by the company Solvay;

glyceryl laurate containing 2 glycerol units, sold by the company Solvay;

sorbitan oleate, sold under the name Span 80 by the company ICI;

sorbitan isostearate, sold under the name Nikkol SI 10R by the company Nikko;

α-butylglucoside cocoate or α-butylglucoside caprate, marketed by the company ULICE.

The ratio by weight of the amount of oil contained in the emulsion in accordance with the invention to the amount of amphiphilic lipid component (oil/lipid) preferably varies from 3 to 6, but may be as high as 10 and includes 2, 3, 4, 5, 6, 7, 8, and 9 and all values and subranges therebetween.

A specific form of the nanoemulsion in accordance with the invention is characterized in that the amphiphilic lipid component additionally contain one or a number of ionic amphiphilic lipids.

Ionic amphiphilic lipids which may be used in the nanoemulsions of the invention include, and are preferably chosen from the group formed by neutralized anionic lipids, amphoteric ionic lipids or alkylsulphonic derivatives.

They are more preferably chosen from the group formed by:

alkaline salts of dicetyl and dimyristyl phosphate;

alkaline salts of cholesterol sulphate;

alkaline salts of cholesterol phosphate;

amino acids containing fatty groups, such as mono- and disodium acylglutamates;

sodium salts of phosphatidic acid;

phospholipids;

alkylsulphonic derivatives of formula: ##STR1## in which R represents a C16 -C22 alkyl radical, in particular C16 H33 and C18 H37 radicals, taken as a mixture or separately, and M is an alkali metal, such as sodium.

The ionic amphiphilic lipids are present in the nanoemulsions of the invention in concentrations preferably ranging from 2 to 10% by weight and more preferably from 5 to 10% by weight with respect to the total weight of the amphiphilic lipid component.

The nanoemulsions in accordance with the invention contain an amount of oil preferably ranging from 5 to 30% by weight with respect to the total weight of the emulsion.

Oils which can be used in the emulsions of the invention include, and are preferentially chosen from, the group formed by:

animal or vegetable oils formed by esters of fatty acids and of polyols, in particular liquid triglycerides, for example sunflower, maize, soybean, gourd, grape seed, sesame and hazelnut oils, fish oils or caprylic/capric triglyceride, or vegetable or animal oils of formula R9 COOR10, in which R9 represents the residue of a higher fatty acid containing from 7 to 19 carbon atoms and R10 represents a branched hydrocarbon chain containing from 3 to 20 carbon atoms, for example purcellin oil;

natural or synthetic essential oils such as, for example, oils of eucalyptus, of lavandin, of lavender, of vetiver, of Litsea cubeba, of lemon, of santal, of rosemary, of camomile, of savory, of nutmeg, of cinnamon, of hyssop, of caraway, of orange, of geranium, of cade and of bergamot;

hydrocarbons, such as hexadecane and liquid paraffin;

halogenated hydrocarbons, in particular fluorocarbons, such as fluoroamines, for example perfluorotributylamine, fluorinated hydrocarbons, for example perfluorodecahydronaphthalene, fluoroesters and fluoroethers;

esters of an inorganic acid and of an alcohol;

ethers and polyethers;

silicones, as a mixture with at least one of the oils defined above, for example decamethylcyclopentasiloxane or dodecamethylcyclohexasiloxane.

The emulsions in accordance with the present invention can contain additives, in order to improve the transparency of the formulation. These additives are preferably chosen from the group formed by:

lower C1 -C8 alcohols, such as ethanol,

glycols, such as glycerol, propylene glycol, 1,3-butylene glycol, dipropylene glycol or polyethylene glycols containing from 4 to 16 ethylene oxide units and preferably from 8 to 12.

Additives, such as those mentioned above, are present in the emulsions of the invention in concentrations preferably ranging from 5 to 30% by weight with respect to the total weight of the emulsion. The alcohols are preferably used at concentrations ranging from 5 to 20% by weight. The glycols are preferably used as concentrations ranging from 2 to 15% by weight.

In addition, the use of the alcohols as defined above, at concentrations greater than or equal to 15% by weight, make it possible to obtain preservative-free emulsions.

The emulsions of the invention can contain water-soluble or liposoluble active principles (agents) having a cosmetic, dermopharmaceutical, etc. activity. The liposoluble active principles are generally thought to be confined in the oily globules of the emulsion, whereas the water-soluble active principles are thought to be confined in the aqueous phase of the emulsion. Mention may be made, as examples of active principles, of vitamins, such as vitamin E and its derivatives, provitamins, such as panthenol, humectants, sunscreens, etc.

The nanoemulsions in accordance with the invention can also contain adjuvants used for the formulation of the nanoemulsion in the form of a lotion, serum, cream or milk, such as gelling agents, preservatives and fragrances. Mention may be made, among the gelling agents which can be used, of cellulose derivatives, such as hydroxypropyl methyl cellulose, fatty alcohols such as stearyl, cetyl and behenyl alcohols, alga derivatives such as satiagum, natural gums such as gum tragacanth and synthetic polymers such as the mixtures of polycarboxyvinyl acids marketed under the name Carbopol by the company Goodrich and the mixture of Na acrylate/acrylamide copolymers marketed under the name Hostacerin PN 73 by the company Hoechst.

The oil globules of the nanoemulsions of the invention preferably have a mean size ranging from 30 to 75 nm and more preferentially from 40 to 60 nm. They can be as large as less than 100 nm and include 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, and 95 nm and all values and subranges therebetween. The size of the globules makes it possible to promote penetration of the active principles into the surface layers of the skin (carrier effect).

The nanoemulsions according to the invention are preferably colorless or possibly slightly bluish and exhibit a transparency, determined by the transmittance coefficient, measured at a wavelength of 600 nm, preferentially ranging from 30 to 90% and more particularly from 50 to 80%.

The nanoemulsions of the invention can be obtained by a process, characterized in that the aqueous phase and the oily phase are mixed, with vigorous stirring, at an ambient temperature of less than 45°C followed by high-pressure homogenization at a pressure greater than 108 Pa and preferably ranging from 12×107 to 18×107 Pa. Such a process makes it possible to produce, at ambient temperature, nanoemulsions which are compatible with heat-sensitive active compounds and which can contain significant amounts of oils and in particular fragrances which contain fatty substances, without denaturing them.

Further subjects of the invention are a composition for topical use such as a cosmetic or dermopharmaceutical composition, characterized in that it is composed of an emulsion as defined above, and the use of the same on the skin, hair, eyes, face, etc.

A further subject of the invention is the use of the nanoemulsions as defined above as the basis for care and/or make-up products for the skin and/or the face and/or the scalp, such as lotions, serums, milks, creams or toilet waters.

Finally, the invention also relates to a non-therapeutic process for caring for the skin or for the scalp, characterized in that a nanoemulsion as defined above is applied to the skin or to the scalp.

The following examples will make it possible to understand the invention better without, however, having a limiting nature.

For the following Examples 1 to 7, the following procedure is used:

the amphiphilic lipids are homogenized with the oils and the lipophilic active principles and adjuvants at a temperature of 45°C in a first phase A;

the hydrophilic active principles and adjuvants are dissolved at a temperature of 20° to 30°C in a second phase B;

then, the phases A and B are mixed using a turbine homogenizer and then homogenization is carried out using a high-pressure homogenizer of the Soavi-Niro type at a pressure of 1500 bars, over 7 passages, the temperature of the product being maintained below 35°C

In the case of Example 7, the gelling agent is added in a phase C which is mixed with the phases A and B using a turbine homogenizer.

PAC Vitamin-Containing Care Water

First Phase

______________________________________
PEG-400 isostearate, sold by the company
4.5%
Unichema
Disodium salt of N-stearoyl-L-glutamic acid,
0.5%
marketed under the name Acylglutamate
HS21 by the Company Ajinomoto (ionic
amphiphilic lipid)
Jojoba oil 6%
Mixture of sunflower, hybrid sunflower,
6%
musk rose and blackcurrant seed oils
Cyclomethicone 7%
Vitamin E acetate 1%
Copherol F1300, marketed by Henkel
0.2%
Stabilized vitamin A palmitate
0.1%
Non-denatured absolute ethanol
15%
______________________________________

Second Phase

______________________________________
Demineralized water 54.7%
Glycerol 5%
______________________________________

An emulsion is obtained in which the size of the oil globules is 63 nm with a transparency, determined by the transmittance coefficient at 600 nm, equal to 40%.

PAC Care Fluid

First Phase

______________________________________
PEG-400 isostearate, sold by the company
4.5%
Unichema
Disodium salt of N-stearoyl-L-glutamic acid,
0.5%
marketed under the name Acylglutamate
HS21 by the Company Ajinomoto (ionic
amphiphilic lipid)
Jojoba oil 5%
Avocado oil 5%
Volatile silicone 9%
Cetyl alcohol 1%
Vitamin E acetate 1%
Copherol F1300 0.2%
Stabilized vitamin A palmitate
0.1%
Non-denatured absolute ethanol
15%
______________________________________

Second Phase

______________________________________
Glycerol 5%
Demineralized water q.s. for
100%
______________________________________

A thick transparent emulsion is obtained in which the size of the globules is 53 nm and the transparency 60%.

PAC Fluid Eyeliner

First Phase

______________________________________
PEG-400 isostearate, sold by the company Unichema
4.5%
Disodium salt of N-stearoyl-L-glutamic acid,
0.5%
marketed under the name Acylglutamate
HS21 by the Company Ajinomoto (ionic
amphiphilic lipid)
Jojoba oil 5%
Light liquid petrolatum 4%
Avacado oil 4%
Volatile silicone 6%
Vitamin E acetate 1%
Copherol F1300 0.2%
______________________________________

Second Phase

______________________________________
Glycerol 5%
Polyethylene glycol containing 8 ethylene
10%
oxide units
Demineralized water q.s. for
100%
______________________________________

An opalescent emulsion is obtained in which the size of the globules is 65 nm and the transparency 42%.

PAC Body Care Fluid

First Phase

______________________________________
PEG-400 isostearate, sold by the company Unichema
4.5%
Disodium salt of N-stearoyl-L-glutamic acid,
0.5%
marketed under the name Acylglutamate
HS21 by the company Ajinomoto (ionic
amphiphilic lipid)
Light liquid petrolatum 7%
Avocado oil 7%
Volatile silicone 6%
Vitamin E acetate 1%
Non-denatured absolute ethanol
15%
______________________________________

Second Phase

______________________________________
Glycerol 5%
Demineralized water q.s. for
100%
______________________________________

A particularly fluid fluid is obtained in which the size of the globules is of the order of 50 nm and the transparency 60%.

PAC Moisturizing Fluid

First Phase

______________________________________
α-Butylglucoside cocoate, marketed by ULICE
4.5%
Disodium salt of N-stearoyl-L-glutamic acid,
0.5%
marketed under the name Acylglutamate
HS21 by the Company Ajinomoto (ionic
amphiphilic lipid)
Jojoba oil 5%
Avocado oil 5%
Volatile silicone 6%
Stearyl heptanoate/stearyl caprylate
2%
Vitamin E acetate 1%
Non-denatured absolute ethanol
15%
______________________________________

Second Phase

______________________________________
Glycerol 6%
Sodium hyaluronate 0.10%
Demineralized water q.s. for
100%
______________________________________

A transparent emulsion is obtained in which the size of the globules is 52 nm and the transparency 58%.

PAC Scented Fluid

First Phase

______________________________________
PEG-400 isostearate, sold by the company Unichema
4.5%
Disodium salt of N-stearoyl-L-glutamic acid,
0.5%
marketed under the name Acylglutamate
HS21 by the Company Ajinomoto (ionic
amphiphilic lipid)
Jojoba oil 4%
Mixture of sunflower, hybrid sunflower,
4%
musk rose and blackcurrant seed oils
Volatile silicone 6%
Fragrance 6%
Non-denatured absolute ethanol
15%
______________________________________

Second Phase

______________________________________
Demineralized water 54.7%
Glycerol 5%
Demineralized water q.s. for
100%
______________________________________

A scented lotion of high persistence is obtained in which the size of the oil globules is 50 nm with a transparency equal to 54%.

PAC Scented Balm

First Phase

______________________________________
α-Butylglucoside cocoate, marketed by ULICE
4.5%
Disodium salt of N-stearoyl-L-glutamic acid,
0.5%
marketed under the name Acylglutamate
HS21 by the Company Ajinomoto (ionic
amphiphilic lipid)
Mixture of sunflower, hybrid sunflower,
7%
musk rose and blackcurrant seed oils
Light liquid petrolatum 7%
Volatile silicone 6%
Fragrance 1.5%
Vitamin E acetate 0.5%
Non-denatured absolute ethanol
15%
______________________________________

Second Phase

______________________________________
Glycerol 5%
Sterile demineralized water q.s. for
100%
______________________________________

Third Phase

______________________________________
Hydroxypropyl cellulose, marketed under
0.4%
the name Methocel E 4 M QG by the company Dow Chemical
Sterile demineralized water 15%
______________________________________

A smooth non-sticky balm is obtained in which the size of the globules is 54 nm and the transparency 53%.

In addition to the specific examples of various components of the invention nanoemulsions given above, those compounds and compositions meeting the functional requirements of the invention components listed in Volumes 1 and 2 of the International Cosmetic Ingredient Dictionary, 6th Ed., 1995, J. A. Wenninger, et al, Eds., published by the Cosmetic, Toiletry and Fragrance Association, incorporated herein by reference, are also to be included. Moreover, each invention component may be a mixture of acceptable compounds or compositions.

This application is based on French Patent Application 95-02268, filed Feb. 27, 1995, incorporated herein by reference.

Simonnet, Jean-Thierry, Legret, Sylvie, Ribier, deceased, Alain

Patent Priority Assignee Title
10010490, Dec 04 2012 Nissan Chemical Industries, Ltd Cosmetic composition comprising cellulose fibers with small fiber diameter and comparatively small aspect ratio
10016364, Jul 18 2005 University of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
10016451, May 31 2007 ANTERIOS, INC Nucleic acid nanoparticles and uses therefor
10029013, Oct 02 2009 JOURNEY MEDICAL CORPORATION Surfactant-free, water-free formable composition and breakable foams and their uses
10086080, Oct 02 2009 JOURNEY MEDICAL CORPORATION Topical tetracycline compositions
10092588, Jul 29 2009 JOURNEY MEDICAL CORPORATION Foamable compositions, breakable foams and their uses
10117812, Nov 29 2002 VYNE THERAPEUTICS INC Foamable composition combining a polar solvent and a hydrophobic carrier
10137200, Oct 02 2009 JOURNEY MEDICAL CORPORATION Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
10213384, Apr 28 2009 JOURNEY MEDICAL CORPORATION Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
10213512, Oct 02 2009 JOURNEY MEDICAL CORPORATION Topical tetracycline compositions
10238746, Oct 02 2009 JOURNEY MEDICAL CORPORATION Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
10265404, Oct 02 2009 JOURNEY MEDICAL CORPORATION Compositions, gels and foams with rheology modulators and uses thereof
10285941, Dec 01 2006 Anterios, Inc. Amphiphilic entity nanoparticles
10322085, Oct 25 2002 VYNE THERAPEUTICS INC Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
10322186, Oct 02 2009 JOURNEY MEDICAL CORPORATION Topical tetracycline compositions
10350166, Jul 29 2009 VYNE THERAPEUTICS INC Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
10363216, Apr 28 2009 JOURNEY MEDICAL CORPORATION Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
10369102, Aug 07 2008 VYNE THERAPEUTICS INC Wax foamable vehicle and pharmaceutical compositions thereof
10398641, Sep 08 2016 JOURNEY MEDICAL CORPORATION Compositions and methods for treating rosacea and acne
10463742, Oct 02 2009 JOURNEY MEDICAL CORPORATION Topical tetracycline compositions
10517882, Oct 02 2009 JOURNEY MEDICAL CORPORATION Method for healing of an infected acne lesion without scarring
10532019, Dec 01 2005 University of Massachusetts Lowell Botulinum nanoemulsions
10576034, Dec 01 2005 University of Massachusetts Lowell Botulinum nanoemulsions
10588858, Apr 28 2009 JOURNEY MEDICAL CORPORATION Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
10610599, Oct 02 2009 JOURNEY MEDICAL CORPORATION Topical tetracycline compositions
10758485, Dec 01 2006 Anterios, Inc. Amphiphilic entity nanoparticles
10821077, Oct 25 2002 VYNE THERAPEUTICS INC Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
10821187, Oct 02 2009 JOURNEY MEDICAL CORPORATION Compositions, gels and foams with rheology modulators and uses thereof
10835613, Oct 02 2009 JOURNEY MEDICAL CORPORATION Compositions, gels and foams with rheology modulators and uses thereof
10849847, Sep 08 2016 JOURNEY MEDICAL CORPORATION Compositions and methods for treating rosacea and acne
10905637, Dec 01 2006 Anterios, Inc. Peptide nanoparticles and uses therefor
10946101, Oct 02 2009 JOURNEY MEDICAL CORPORATION Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
10967063, Oct 02 2009 JOURNEY MEDICAL CORPORATION Surfactant-free, water-free formable composition and breakable foams and their uses
10980888, Aug 29 2007 Agency for Science, Technology and Research Sugar-based surfactant microemulsions containing essential oils for cosmetic and pharmaceutical use
11033491, Mar 11 2005 VYNE THERAPEUTICS INC Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
11052030, Sep 29 2015 Shiseido Company, Ltd. Method for manufacturing microemulsion-type cosmetic
11103454, Aug 07 2007 VYNE THERAPEUTICS INC Wax foamable vehicle and pharmaceutical compositions thereof
11162136, Apr 15 2020 ENUMERIX, INC Systems and methods for generation of emulsions with suitable clarity with applications of use
11219631, Jul 29 2009 JOURNEY MEDICAL CORPORATION Foamable compositions, breakable foams and their uses
11242558, Apr 15 2020 ENUMERIX, INC Systems and methods for generation of emulsions with suitable clarity with applications of use
11311496, Nov 21 2016 EIRION THERAPEUTICS, INC Transdermal delivery of large agents
11324691, Sep 08 2016 JOURNEY MEDICAL CORPORATION Compositions and methods for treating rosacea and acne
11414450, Aug 28 2017 REVAGENIX, INC Aminoglycosides and uses thereof
11433025, Dec 07 2007 JOURNEY MEDICAL CORPORATION Oil foamable carriers and formulations
11447817, Apr 15 2020 Enumerix, Inc. Systems and methods for generation of emulsions with suitable clarity with applications of use
11542546, Apr 15 2020 Enumerix, Inc. Systems and methods for generation of emulsions with suitable clarity with applications of use
11673907, Apr 03 2018 REVAGENIX, INC Modular synthesis of aminoglycosides
11814619, Jun 04 2021 ENUMERIX, INC Compositions, methods, and systems for single cell barcoding and sequencing
11834714, Dec 20 2021 ENUMERIX, INC Detection and digital quantitation of multiple targets
6039936, Nov 15 1996 L Oreal Nanoemulsion based on non-ionic and cationic amphiphilic lipids and uses thereof
6071524, Nov 10 1994 L'Oreal Oily phase in aqueous phase dispersion stabilized by cubic gel particles and method of making
6274150, Dec 23 1998 L Oreal Nanoemulsion based on phosphoric acid fatty acid esters and its uses in the cosmetics, dermatological, pharmaceutical, and/or ophthalmological fields
6335022, Dec 17 1998 L Oreal Nanoemulsion based on oxyethylenated or non-oxyethylenated sorbitan fatty esters, and its uses in the cosmetics, dermatological and/or ophthalmological fields
6461625, Feb 02 1999 L Oreal Nanoemulsion based on alkoxylated alkenyl succinates or alkoxylated alkenyl succinates of glucose and its uses in the cosmetics, dermatological, opthalmological and/or pharmaceutical fields
6464990, Jan 05 1999 L'Oreal Nanoemulsion based on ethylene oxide and propylene oxide block copolymers and its uses in the cosmetics, dermatological and/or ophthalmological fields
6468551, Oct 10 1996 Beiersdorf AG Cosmetic or dermatological preparations based on emulsifiers which are free from ethylene oxide and propylene oxide, for the preparation of microemulsion gels
6488780, Nov 15 1996 L'Oreal S.A. Detergent cosmetic compositions and use thereof
6491902, Jan 29 2001 Salvona LLC Controlled delivery system for hair care products
6537561, Feb 27 1997 Nippon Shinyaku Co., Ltd. Fat emulsion for oral administration
6541029, Aug 31 1998 Nipro Corporation Nutrient infusion preparation
6559183, Nov 12 1998 BIOFRONTERA BIOSCIENCE GMBH Nano-emulsion of 5-aminolevulinic acid
6689371, Dec 14 1998 L Oreal Nanoemulsion based on sugar fatty esters or on sugar fatty ethers and its uses in the cosmetics, dermatological and/or ophthalmological fields
6773627, Jun 29 2000 Children's Hospital Research Foundation Cubic liquid crystalline compositions and methods for their preparation
6774101, Oct 20 2000 Firmenich SA Alcohol-free perfuming composition
6979440, Jan 29 2001 SALVONA L L C Compositions and method for targeted controlled delivery of active ingredients and sensory markers onto hair, skin, and fabric
6998426, Jul 13 2000 L Oreal Nanoemulsion containing nonionic polymers, and its uses
7153516, Jul 02 2001 Color Access, Inc. Ringing nanogel compositions
7300912, Aug 10 2005 Foaming cleansing preparation and system comprising coated acid and base particles
7763663, Dec 19 2001 MASSACHUSETTS, UNIVERSITY OF Polysaccharide-containing block copolymer particles and uses thereof
8114385, Aug 04 2003 VYNE THERAPEUTICS INC Oleaginous pharmaceutical and cosmetic foam
8114389, Jan 21 2000 L'Oreal S.A. Nanoemulsions comprising at least one amphiphilic lipid, at least one oil, and at least one nonionic polymer, and uses thereof
8119106, Apr 28 2003 VYNE THERAPEUTICS INC Foamable iodine compositions
8119109, Oct 25 2002 VYNE THERAPEUTICS INC Foamable compositions, kits and methods for hyperhidrosis
8119150, Oct 25 2002 VYNE THERAPEUTICS INC Non-flammable insecticide composition and uses thereof
8318181, Dec 01 2005 University of Massachusetts Lowell Botulinum nanoemulsions
8343945, Dec 07 2007 JOURNEY MEDICAL CORPORATION Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
8362091, Aug 04 2003 VYNE THERAPEUTICS INC Foamable vehicle and pharmaceutical compositions thereof
8435498, Oct 24 2002 VYNE THERAPEUTICS INC Penetrating pharmaceutical foam
8486374, Apr 28 2004 VYNE THERAPEUTICS INC Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
8486375, Apr 28 2003 VYNE THERAPEUTICS INC Foamable compositions
8486376, Oct 25 2002 VYNE THERAPEUTICS INC Moisturizing foam containing lanolin
8512718, Jul 03 2000 VYNE THERAPEUTICS INC Pharmaceutical composition for topical application
8513311, Nov 22 2005 Nestec S A Oil-in-water emulsion and its use for the delivery of functionality
8518376, Dec 07 2007 JOURNEY MEDICAL CORPORATION Oil-based foamable carriers and formulations
8518378, Aug 04 2003 VYNE THERAPEUTICS INC Oleaginous pharmaceutical and cosmetic foam
8618081, Oct 02 2009 JOURNEY MEDICAL CORPORATION Compositions, gels and foams with rheology modulators and uses thereof
8636982, Aug 07 2007 VYNE THERAPEUTICS INC Wax foamable vehicle and pharmaceutical compositions thereof
8703105, Aug 04 2003 VYNE THERAPEUTICS INC Oleaginous pharmaceutical and cosmetic foam
8709385, Jan 14 2008 VYNE THERAPEUTICS INC Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
8722021, Oct 25 2002 VYNE THERAPEUTICS INC Foamable carriers
8722131, Sep 07 2010 DSM NUTRITIONAL PRODUCTS AG Comestible emulsions
8741265, Oct 25 2002 VYNE THERAPEUTICS INC Penetrating pharmaceutical foam
8760906, Nov 24 2009 OVONYX MEMORY TECHNOLOGY, LLC Techniques for reducing disturbance in a semiconductor memory device
8795635, Nov 14 2006 VYNE THERAPEUTICS INC Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
8795693, Aug 04 2003 VYNE THERAPEUTICS INC Compositions with modulating agents
8834903, Dec 14 1998 L'Oreal Nanoemulsion based on sugar fatty esters or on sugar fatty ethers and its uses in the cosmetics, dermatological and/or ophthalmological fields
8840869, Oct 25 2002 VYNE THERAPEUTICS INC Body cavity foams
8865139, Oct 02 2009 JOURNEY MEDICAL CORPORATION Topical tetracycline compositions
8871184, Oct 02 2009 JOURNEY MEDICAL CORPORATION Topical tetracycline compositions
8900553, Dec 07 2007 JOURNEY MEDICAL CORPORATION Oil and liquid silicone foamable carriers and formulations
8900554, Nov 29 2002 VYNE THERAPEUTICS INC Foamable composition and uses thereof
8920786, Jun 19 2007 Cognis IP Management GmbH Shampoo composition having improved care properties
8945516, Oct 02 2009 JOURNEY MEDICAL CORPORATION Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
8992896, Oct 02 2009 JOURNEY MEDICAL CORPORATION Topical tetracycline compositions
8999893, Feb 04 2008 Dow Agrosciences LLC Stabilized oil-in-water emulsions including meptyl dinocap
9050253, Aug 04 2003 VYNE THERAPEUTICS INC Oleaginous pharmaceutical and cosmetic foam
9072667, Jul 29 2009 VYNE THERAPEUTICS INC Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
9101662, Aug 04 2003 VYNE THERAPEUTICS INC Compositions with modulating agents
9161916, Dec 07 2007 JOURNEY MEDICAL CORPORATION Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
9161921, Dec 28 2010 Colloidal carrier system with penetration properties for encapsulating lipophilic active agents and oils for topical use
9167813, Jul 29 2009 VYNE THERAPEUTICS INC Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
9185905, Mar 07 2008 CORTEVA AGRISCIENCE LLC Stabilized oil-in-water emulsions including agriculturally active ingredients
9211259, Nov 29 2002 VYNE THERAPEUTICS INC Antibiotic kit and composition and uses thereof
9265725, Oct 25 2002 VYNE THERAPEUTICS INC Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
9320705, Oct 25 2002 VYNE THERAPEUTICS INC Sensation modifying topical composition foam
9345651, Jan 24 2011 Chanel Parfums Beaute Oil-in-water emulsion composition and method for producing the same
9426982, Feb 04 2008 Dow Agrosciences LLC Stabilized oil-in-water emulsions including agriculturally active ingredients
9439857, Nov 30 2007 VYNE THERAPEUTICS INC Foam containing benzoyl peroxide
9486408, Dec 01 2005 University of Massachusetts Lowell Botulinum nanoemulsions
9486409, Dec 01 2006 Anterios, Inc. Peptide nanoparticles and uses therefor
9492412, Oct 25 2002 VYNE THERAPEUTICS INC Penetrating pharmaceutical foam
9539208, Oct 25 2002 VYNE THERAPEUTICS INC Foam prepared from nanoemulsions and uses
9549898, Dec 07 2007 JOURNEY MEDICAL CORPORATION Oil and liquid silicone foamable carriers and formulations
9572775, Jul 29 2009 VYNE THERAPEUTICS INC Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
9622947, Oct 25 2002 VYNE THERAPEUTICS INC Foamable composition combining a polar solvent and a hydrophobic carrier
9636405, Aug 04 2003 VYNE THERAPEUTICS INC Foamable vehicle and pharmaceutical compositions thereof
9649275, Nov 28 2007 Commonwealth Scientific and Industrial Research Organisation Nanoemulsions
9662298, Aug 07 2008 VYNE THERAPEUTICS INC Wax foamable vehicle and pharmaceutical compositions thereof
9668972, Oct 25 2002 VYNE THERAPEUTICS INC Nonsteroidal immunomodulating kit and composition and uses thereof
9675700, Oct 02 2009 JOURNEY MEDICAL CORPORATION Topical tetracycline compositions
9682021, Nov 14 2006 VYNE THERAPEUTICS INC Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
9713643, Oct 25 2002 VYNE THERAPEUTICS INC Foamable carriers
9724299, Dec 01 2006 Anterios, Inc. Amphiphilic entity nanoparticles
9795564, Dec 07 2007 JOURNEY MEDICAL CORPORATION Oil-based foamable carriers and formulations
9812179, Nov 24 2009 OVONYX MEMORY TECHNOLOGY, LLC Techniques for reducing disturbance in a semiconductor memory device
9849142, Oct 02 2009 JOURNEY MEDICAL CORPORATION Methods for accelerated return of skin integrity and for the treatment of impetigo
9884017, Apr 28 2009 JOURNEY MEDICAL CORPORATION Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
Patent Priority Assignee Title
EP334777A1,
EP490053A1,
EP516508A1,
EP572080A1,
////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Feb 26 1996L'Oreal(assignment on the face of the patent)
Jun 11 1996SIMONNET, JEAN-THIERRYL OrealASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0080450503 pdf
Jun 11 1996LEGRET, SYLVIEL OrealASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0080450503 pdf
Jun 12 1996RIBIER, ALAINL OrealASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0080450503 pdf
Date Maintenance Fee Events
Feb 10 1999ASPN: Payor Number Assigned.
Sep 27 2001M183: Payment of Maintenance Fee, 4th Year, Large Entity.
Oct 28 2005M1552: Payment of Maintenance Fee, 8th Year, Large Entity.
Oct 21 2009M1553: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
May 19 20014 years fee payment window open
Nov 19 20016 months grace period start (w surcharge)
May 19 2002patent expiry (for year 4)
May 19 20042 years to revive unintentionally abandoned end. (for year 4)
May 19 20058 years fee payment window open
Nov 19 20056 months grace period start (w surcharge)
May 19 2006patent expiry (for year 8)
May 19 20082 years to revive unintentionally abandoned end. (for year 8)
May 19 200912 years fee payment window open
Nov 19 20096 months grace period start (w surcharge)
May 19 2010patent expiry (for year 12)
May 19 20122 years to revive unintentionally abandoned end. (for year 12)